Evidence map›Paper›PMID 38527432›Full record

ReviewInternational archives of allergy and immunology2024

"Air That Once Was Breath" Part 2: Wildfire Smoke and Airway Disease - "Climate Change, Allergy and Immunology" Special IAAI Article Collection: Collegium Internationale Allergologicum Update 2023.

Willis S Bowman, Rebecca J Schmidt, Gursharan K Sanghar, George R Thompson Iii, Hong Ji, Amir A Zeki, Angela Haczku

Open access · greenAbstract readReview
In one paragraph

Review in International archives of allergy and immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Wildfire and asthma - The prospective interventions.The World Allergy Organization journal · 2025
    Review
  2. Article
  3. Real-life observation of wildfire smoke-impaired COVID-19 vaccine immunity.The Journal of allergy and clinical immunology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Willis S Bowman
Rebecca J Schmidt
Gursharan K Sanghar
George R Thompson Iii
Hong Ji
Amir A Zeki
Angela Haczku

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
IND enabling development of LGM2605 as adjuvant treatment for asthmaR42AI132012 · NIAID · LIGNAMED, LLC · PI HACZKU, ANGELA, SIELECKI, THAIS MOTRIA · 2019 to 2021
$3.0M
Role of TET1 in airway epithelium and childhood asthmaR01AI141569 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI JI, HONG · 2019 to 2023
$3.0M
Reducing Airway Smooth Muscle Tone Using Inhaled StatinsR01HL148715 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZEKI, AMIR A. · 2020 to 2024
$2.3M
Mechanisms of social-stress enhanced allergic airway response in a mouse modelR01AI072197 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HACZKU, ANGELA · 2010 to 2014
$2.0M
Regulation of Inflammation in Asthma by Fas LigandR01HL076646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI HACZKU, ANGELA · 2005 to 2009
$1.8M
Surfactant-Protein Innate Immunity in an Asthma ModelR01AI055593 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HACZKU, ANGELA · 2004 to 2008
$1.6M
Effects of ozone exposure on expression and function of surfactant protein DRC1ES018505 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI HACZKU, ANGELA · 2009 to 2010
$1.0M
Asthma, anxiety and GR abnormalities in non-human primatesR21AI116121 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HACZKU, ANGELA · 2015 to 2016
$448k
Surfactant-Protein Innate Immunity in an Asthma ModelR21AI055593 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HACZKU, ANGELA · 2003 to 2003
$308k
Effects of LGM2605 on a Primate Model of AsthmaR41AI132012 · NIAID · LIGNAMED, LLC · PI HACZKU, ANGELA, SIELECKI, THAIS MOTRIA · 2017 to 2017
$278k
NHLBI NIH HHS R01 HL076646NHLBI NIH HHS R01 HL148715NIAID NIH HHS R01 AI055593NIAID NIH HHS R01 AI072197NIAID NIH HHS R01 AI141569NIAID NIH HHS R21 AI055593NIAID NIH HHS R21 AI116121NIAID NIH HHS R41 AI132012NIAID NIH HHS R42 AI132012NIEHS NIH HHS RC1 ES018505NIH HHS P51 OD011107
6 · The paper itself

Abstract

backgroundPopulation growth and climate change have led to more frequent and larger wildfires, increasing the exposure of individuals to wildfire smoke. Notably, asthma exacerbations and allergic airway sensitization are prominent outcomes of such exposure. SUMMARY: Key research questions relate to determining the precise impact on individuals with asthma, including the severity, duration, and long-term consequences of exacerbations. Identifying specific risk factors contributing to vulnerability, such as age, genetics, comorbidities, or environmental factors, is crucial. Additionally, reliable biomarkers for predicting severe exacerbations need exploration. Understanding the long-term health effects of repeated wildfire smoke exposures in individuals with asthma and addressing healthcare disparities are important research areas. KEY MESSAGES: This review discusses the need for comprehensive research efforts to better grasp wildfire smoke-induced respiratory health, particularly in vulnerable populations such as farmworkers, firefighters, pregnant women, children, the elderly, and marginalized communities. Effective mitigation would require addressing the current limitations we face by supporting research aimed at a better understanding of wildfire smoke-induced airway disease.

Indexed as

Climate ChangeSmokeWildfiresAsthmaEnvironmental ExposureHumansSmokeAsthmaChronic obstructive pulmonary diseasePsychosocial stressVulnerability to airway diseaseWildfire smoke

Identifiers

PMID38527432
PMCPMC11548886
OpenAlexW4394738454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.